Fractyl Health Inc. has announced potent new preclinical results from RJVA-002, a dual GIP/GLP-1 gene therapy candidate for obesity, developed under its Rejuva® platform. In a translational obesity model, a single administration of RJVA-002 achieved approximately 30% weight loss at five weeks, with weight loss not yet plateaued. The results suggest the potential for significant and durable weight loss from a one-time intervention. RJVA-002 is the second candidate from Fractyl's gene therapy platform, which aims to enable long-term remission of obesity and type 2 diabetes (T2D) by reprogramming pancreatic islet cells to produce metabolic hormones. Results from ongoing studies at longer time points and with additional metabolic measurements will be presented at an upcoming scientific congress. The company's first Rejuva candidate, RJVA-001, is expected to enter first-in-human clinical trials for T2D in 2026, pending regulatory authorization.